# Teduglutide for Enterocutaneous Fistula (ECF)

> **NCT02889393** · PHASE2 · COMPLETED · sponsor: **Daniel Dante Yeh** · enrollment: 6 (actual)

## Conditions studied

- Postoperative Fistula

## Interventions

- **DRUG:** Teduglutide
- **OTHER:** Standard of Care

## Key facts

- **NCT ID:** NCT02889393
- **Lead sponsor:** Daniel Dante Yeh
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-31
- **Primary completion:** 2020-07-15
- **Final completion:** 2021-07-15
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2021-10-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02889393

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02889393, "Teduglutide for Enterocutaneous Fistula (ECF)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02889393. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*